CytoDyn Inc. Company Review & Valuation

CYDY
OTC Markets
Latest Price
1.50USD
Market Capitalization
990.29mUSD

About CytoDyn Inc.

CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection.

Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.

The company is based in Vancouver, Washington.

Industry
Biotechnology
HQ Location
Vancouver, Washington

Stock Price

Price data not available for CytoDyn Inc..

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2021 Valuu Analytics Sàrl